Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia

Journal of Clinical Oncology

Volumn 32, Issue 4, 2014, Pages 306-311

  Dusetzina, Stacie B ^a,b   Winn, Aaron N ^b   Abel, Gregory A ^c   Huskamp, Haiden A ^d   Keating, Nancy L ^d,e  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; COMORBIDITY; CONTROLLED STUDY; DRUG COST; DRUG WITHDRAWAL; FEMALE; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREFERRED PROVIDER ORGANIZATION; PRIORITY JOURNAL; PROPENSITY SCORE; SENSITIVITY ANALYSIS; COST; DRUG ANTAGONISM; ECONOMICS; ENZYMOLOGY; HEALTH CARE COST; INSURANCE; MIDDLE AGED; STATISTICS; UNITED STATES;

ADULT; ANTINEOPLASTIC AGENTS; BENZAMIDES; COST SHARING; DRUG COSTS; FEMALE; HEALTH EXPENDITURES; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; UNITED STATES;

EID: 84897019740     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.9123     Document Type: Article

References (34)

1. Experts in Chronic Myeloid Leukemia: The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts. Blood 121:4439-4442, 2013
2. Gambacorti-Passerini C, Antolini L, Mahon FX, et al: Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 103:553-561, 2011
3. Noens L, van Lierde MA, De Bock R, et al: Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study. Blood 113:5401-5411, 2009
4. Wu EQ, Johnson S, Beaulieu N, et al: Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin 26:61-69, 2010
5. Marin D, Bazeos A, Mahon FX, et al: Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28:2381-2388, 2010
6. Ibrahim AR, Eliasson L, Apperley JF, et al: Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 117:3733-3736, 2011
7. Landon BE, Rosenthal MB, Normand SL, et al: Incentive formularies and changes in prescription drug spending. Am J Manag Care 13:360-369, 2007 (Pubitemid 46983133)
8. Smith C, Cowan C, Heffler S, et al: National health spending in 2004: Recent slowdown led by prescription drug spending. Health Aff (Millwood) 25:186-196, 2006 (Pubitemid 43202441)
9. Robinson JC: Insurers' strategies for managing the use and cost of biopharmaceuticals. Health Aff (Millwood) 25:1205-1217, 2006
10. Neugut AI, Subar M, Wilde ET, et al: Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 29:2534-2542, 2011
11. Goldman DP, Joyce GF, Escarce JJ, et al: Pharmacy benefits and the use of drugs by the chronically ill. JAMA 291:2344-2350, 2004 (Pubitemid 38656301)
12. Goldman DP, Joyce GF, Zheng Y: Prescription drug cost sharing: Associations with medication and medical utilization and spending and health. JAMA 298:61-69, 2007 (Pubitemid 47026771)
13. Huskamp HA, Deverka PA, Epstein AM, et al: The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med 349:2224-2232, 2003 (Pubitemid 37485139)
14. Huskamp HA, Deverka PA, Epstein AM, et al: Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children. Arch Gen Psychiatry 62:435-441, 2005 (Pubitemid 40471693)
15. Goldman DP, Joyce GF, Lawless G, et al: Benefit design and specialty drug use. Health Aff (Millwood) 25:1319-1331, 2006 (Pubitemid 44497632)
16. Karaca-Mandic P, Joyce GF, Goldman DP, et al: Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis. Health Serv Res 45:1227-1250, 2010
17. Kim YA, Rascati KL, Prasla K, et al: Retrospective evaluation of the impact of copayment increases for specialty medications on adherence and persistence in an integrated health maintenance organization system. Clin Ther 33:598-607, 2011
18. Truven Health Analytics: Comparative Effectiveness Research: Research and Analytics, 2012. http://truvenhealth.com/products/comparative-effectiveness- research.aspx
19. Steiner JF, Prochazka AV: The assessment of refill compliance using pharmacy records: Methods, validity, and applications. J Clin Epidemiol 50:105-116, 1997 (Pubitemid 27089212)
20. Hess LM, Raebel MA, Conner DA, et al: Measurement of adherence in pharmacy administrative databases: A proposal for standard definitions and preferred measures. Ann Pharmacother 40:1280-1288, 2006 (Pubitemid 44204957)
21. Klabunde CN, Potosky AL, Legler JM, et al: Development of a comorbidity index using physician claims data. J Clin Epidemiol 53:1258-1267, 2000 (Pubitemid 32007842)
22. Farley JF, Harley CR, Devine JW: A comparison of comorbidity measurements to predict healthcare expenditures. Am J Manag Care 12:110-119, 2006
23. Schneeweiss S, Seeger JD, Maclure M, et al: Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 154:854-864, 2001 (Pubitemid 33000813)
24. Sato T, Matsuyama Y: Marginal structural models as a tool for standardization. Epidemiology 14:680-686, 2003 (Pubitemid 40417015)
25. Robins JM, Hernán MA, Brumback B: Marginal structural models and causal inference in epidemiology. Epidemiology 11:550-560, 2000 (Pubitemid 30660034)
26. Hernán MA, Brumback B, Robins JM: Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 11:561-570, 2000 (Pubitemid 30660035)
27. Lin DY, Psaty BM, Kronmal RA: Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics 54:948-963, 1998 (Pubitemid 28429289)
28. Vanderweele TJ, Arah OA: Bias formulas for sensitivity analysis of unmeasured confounding for general outcomes, treatments, and confounders. Epidemiology 22:42-52, 2011
29. Osterberg L, Blaschke T: Adherence to medication. N Engl J Med 353:487-497, 2005 (Pubitemid 41127293)
30. Lacro JP, Dunn LB, Dolder CR, et al: Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. J Clin Psychiatry 63:892-909, 2002 (Pubitemid 35231730)
31. U.S. Government Accountability Office: Medicare Part D: Spending, Beneficiary Cost Sharing, and Cost-Containment Efforts for High-Cost Drugs Eligible for a Specialty Tier. GAO-10-242, Report to the Chairman, Subcommittee on Health, Committee on Ways and Means, House of Representatives, 2010
32. Centers for Medicare & Medicaid Services (CMS): Prescription Drug Plan Formulary, Pharmacy Network, and Pricing Information Files, 2011. www.cms.gov/Research-Statistics-Data-and-Systems/Files-for-Order/ NonIdentifiableDataFiles/ PrescriptionDrugPlanFormularyPharmacyNetworkandPricingInformationFiles.html
33. Howlader N, Noone AM, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2010. Bethesda, MD, National Cancer Institute, 2013. http://seer.cancer.gov/csr/1975-2010/
34. Gellad WF, Grenard JL, Marcum ZA: A systematic review of barriers to medication adherence in the elderly: Looking beyond cost and regimen complexity. Am J Geriatric Pharmacother 9:11-23, 2011